Skip to content

Bachem Holding AG

🇬🇧XLON.0QNDUnited KingdomNot reported

£81.35GBPdown -1.55 (-1.87%)ClosedEnd of day2:45 PM

Price£81.35-1.55 (-1.87%)

Latest anomalies

Very negative 15 detected in the last 120 days

  • High: 5
  • Medium: 4
  • Low: 6
  • 52-week high: the price is trading close to this level

    Price Low

  • Volume: a spike above the 20-day average

    Price High

  • Volume: a spike above the 20-day average

    Price Medium

  • Volume: a spike above the 20-day average

    Price High

  • Overnight gap: a gap up from the prior close

    Price Low

View all anomalies

Free with a Finzer account.

Profile

  • United Kingdom

Identity

Type
Stock
ISIN
Not reported
CUSIP
Not reported

Company

Employees
2,292
Headquarters
Bubendorf, United Kingdom

Market

Shares outstanding
13.6M
Market cap
£5.57B

Key dates

Next earnings
Mar 4, 2027

Highlights

Day range£81.00 - £83.75
today's session
52-week range£48.70 - £84.00
from 248 sessions
Market cap
£5.57B
EPS LTM
CHF 1.97
P/E LTM
46.32
Div yield
1.23%

Fundamentals (LTM)

Revenue
CHF 805.08M+61.35%up year on year
Net income
CHF 147.78M+50.53%up year on year
Gross margin
29.63%-6.09%down year on year
Free cash flow
-CHF 91.19M-104.09%down year on year

View all financials

Latest news

News is not sourced for this exchange.

Business summary

Bachem Holding AG is listed on London Stock Exchange (United Kingdom) under the ticker 0QND. Its market capitalisation is £5.57B, from 13.6M shares outstanding, as of . Across the 248 trading sessions to the shares traded between £48.70 and £84.00, and the last close of £81.35 sits 92% of the way up that range. The company is headquartered in Bubendorf, United Kingdom, and employs about 2,292 people. This is the London Stock Exchange listing of Bachem Holding AG; its primary listing is BANB on SIX Swiss Exchange.

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland.